SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S on behalf of investors who purchased or acquired the company's securities between May 7, 2025, and July 28, 2025, alleging misrepresentations regarding the company's growth potential related to its diabetes/obesity drug, GLP-1 [1][2]. Group 1 - The lawsuit claims that the defendants made misrepresentations concerning Novo's growth potential stemming from the Company's diabetes/obesity drug, GLP-1 [2]. - Investors who purchased Novo securities during the specified period are encouraged to discuss their legal rights and options [2]. - A lead plaintiff must file papers by September 30, 2025, to represent the class in the litigation [3]. Group 2 - Bernstein Liebhard LLP has recovered over $3.5 billion for its clients since 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].